MS and Demyelinating Disorders

No new safety signals were observed in the combined analysis of ponesimod from the phase 2b core study and extension study.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 11, 2020.

Treatment-naïve patients showed consistent results with the overall study population that was observed in the ASCLEPIOS I and II trials.

Patients with relapsing multiple sclerosis and high levels of fatigue were less likely to be employed full-time than those with MS with low fatigue.

Financial self-efficacy and having at least 1 relapse were identified as independent predictors of financial toxicity among patients with multiple sclerosis.

Leah Croll, MD, a neurology resident on the front lines of the COVID-19 pandemic, shares details from her study on the psychosocial impact on physicians and her first-hand experience.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 4, 2020.

New biomarkers of disease activity may help better vet investigational therapies aimed at slowing the insidious neurodegeneration seen in primary progressive multiple sclerosis.